nach oben

Current Infectious Disease Reports

Erschienen in:

01.09.2010

Adjunct Therapy for Sepsis: How Early?

verfasst von: Djillali Annane

Erschienen in: Current Infectious Disease Reports | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Sepsis is a leading cause of death worldwide. The management of patients is primarily based on curing the infectious process with anti-infective drugs and/or surgical drainage. Simultaneously, treatment includes optimization of oxygen use by tissues via appropriate oxygen therapy and respiratory and hemodynamic management. At best, initiating appropriate anti-infective and symptomatic treatments should lead to patient improvement within a few hours. Activated protein C and hydrocortisone are the only two available adjunct therapies for sepsis. These treatments should optimally be started within 24 hours of the onset of shock. They should be initiated in those patients who did not adequately respond after 6 hours of optimal anti-infective and symptomatic treatments.

Angus DC, Linde-Zwirble WT, Lidicker J, et al.: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303–1310.CrossRefPubMed

Annane D, Sébille V, Charpentier C, et al.: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002, 288:862–871.CrossRefPubMed

Bernard GR, Vincent JL, Laterre PF, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699–709.CrossRefPubMed

• Riedemann T, Patchev AV, Cho K, Almeida OF: Corticosteroids: way upstream. Mol Brain 2010, 3:2. This article provides a comprehensive update of knowledge about corticosteroids’ mechanisms of action.CrossRefPubMed

Annane D: Glucocorticoids in the treatment of severe sepsis and septic shock. Curr Opin Crit Care 2005, 11:449–453.CrossRefPubMed

Muhlfelder TW, Niemetz J, Kang S: Glucocorticoids inhibit the generation of leukocyte procoagulant (tissue factor) activity. Blood 1982, 60:1169–1172.PubMed

van Giezen JJ, Jansen JW: Inhibition of fibrinolytic activity in-vivo by dexamethasone is counterbalanced by an inhibition of platelet aggregation. Thromb Haemost 1992, 68:69–73.PubMed

Jorgensen KA, Sorensen P, Freund L: Effect of glucocorticosteroids on some coagulation tests. Acta Haematol 1982, 68:39–42.CrossRefPubMed

Patrassi GM, Sartori MT, Livi U, et al.: Impairment of fibrinolytic potential in long-term steroid treatment after heart transplantation. Transplantation 1997, 64:1610–1614.CrossRefPubMed

10.

`Schmidt S, Rainer J, Ploner C, et al.: Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ 2004, 11(Suppl 1):S45–S55.CrossRefPubMed

11.

Cronin L, Cook DJ, Carlet J, et al.: Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995, 23:1430–1439.CrossRefPubMed

12.

Annane D, Sébille V, Troché G, et al.: A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000, 283:1038–1045.CrossRefPubMed

13.

• Marik PE, Pastores SM, Annane D, et al.: Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008, 36:1937–1949. This article provides a comprehensive approach to the rationale and clinical evidence for the use of corticosteroids in critical illness.CrossRefPubMed

14.

•• Annane D, Bellissant E, Bollaert PE, et al.: Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009, 301:2362–2375. This systematic review clearly establishes the current evidence favoring the use of corticosteroids in septic shock. In addition, it provides useful information on the practical modalities for using corticosteroids in septic shock.CrossRefPubMed

15.

•• COIITSS Study Investigators, Annane D, Cariou A, Maxime V, et al.: Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA 2010, 303:341–348. This is the first multicenter, randomized, controlled trial investigating the benefit-to-risk ratio of normalizing blood glucose levels in corticosteroid-treated patients. The study demonstrated that tight glucose control was not superior to moderate glucose control.CrossRefPubMed

16.

•• Sprung C, Annane D, Keh D, et al.: The CORTICUS randomized, double-blind, placebo-controlled study of hydrocortisone therapy in patients with septic shock. N Engl J Med 2008, 358:111–124. This article challenges the benefit of corticosteroids in septic shock. Although hydrocortisone therapy hastens shock reversal and organ dysfunction resolution, no evidence was shown for survival benefit and there was an apparent increase in superinfections.CrossRefPubMed

17.

• Dellinger RP, Levy MM, Carlet JM, et al.: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296–327. This article provides the current guidelines for the management of sepsis.CrossRefPubMed

18.

Hinshaw LB, Archer LT, Beller-Todd BK, et al.: Survival of primates in lethal septic shock following delayed treatment with steroid. Circ Shock 1981, 8:291–300.PubMed

19.

Cicarelli DD, Vieira JE, Bensenor FE: Early dexamethasone treatment for septic shock patients: a prospective randomized clinical trial. Sao Paulo Med J 2007, 125:237–241.CrossRefPubMed

20.

Yildiz O, Doganay M, Aygen B, et al.: Physiologic-dose steroid therapy in sepsis. Crit Care 2002, 6:251–259.CrossRefPubMed

21.

Oppert M, Schindler R, Husung C, et al.: Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med 2005, 33:2457–2464.CrossRefPubMed

22.

Tandan SM, Guleria R, Gupta N: Low dose steroids and adrenocortical insufficiency in septic shock: a double-blind randomised controlled trial from India [abstract]. Proceedings of the American Thoracic Society Meeting. New York: American Thoracic Society; 2005:A24.

23.

Bollaert PE, Charpentier C, Levy B, et al.: Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998, 26:645–650.CrossRefPubMed

24.

Briegel J, Forst H, Haller M, et al.: Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999, 27:723–732.CrossRefPubMed

25.

Chawla K, Kupfer Y, Tessler S: Hydrocortisone reverses refractory septic shock. Crit Care Med 1999, 27:A33.CrossRef

26.

•• Meduri GU, Golden E, Freire AX, et al.: Methylprednisolone infusion in early ARDS: result of a randomised controlled trial. Chest 2007, 131:954–963. This article describes the first multicenter trial of moderate doses of corticosteroids in early ARDS patients. There was strong evidence for morbidity benefits.CrossRefPubMed

27.

Annane D, Bellissant E, Cavaillon JM: Septic shock. Lancet 2005, 365:63–78.

28.

Toussaint S, Gerlach H: Activated protein C for sepsis. N Engl J Med 2009, 361:2646–2652.CrossRefPubMed

29.

Levi M, van der Poll T: Recombinant human activated protein C: current insights into its mechanism of action. Crit Care 2007, 11(Suppl 5):S3.CrossRefPubMed

30.

Yuksel M, Okajima K, Uchiba M, et al.: Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thromb Haemost 2002, 88:267–273.PubMed

31.

Cheng T, Liu D, Griffin JH, et al.: Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003, 9:338–342.CrossRefPubMed

32.

Dömötör E, Benzakour O, Griffin JH, et al.: Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. Blood 2003, 101:4797–4801.CrossRefPubMed

33.

Mosnier LO, Griffin JH: Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J 2003, 373:65–70.CrossRefPubMed

34.

Montori VM, Devereaux PJ, Adhikari NK, et al.: Randomized trials stopped early for benefit: a systematic review. JAMA 2005, 294:2203–2209.CrossRefPubMed

35.

Ely EW, Laterre P-F, Angus DC, et al.: Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003, 31:12–19.CrossRefPubMed

36.

Abraham E, Laterre PF, Garg R, et al.: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005, 353:1332–1341.CrossRefPubMed

37.

•• Nadel S, Goldstein B, Williams MD, et al.: Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007, 369:836–843. This was the largest trial of activated protein C in children. There was no apparent benefit and an increased risk of serious bleeding.CrossRefPubMed

38.

• Marti-Carvajal A, Salanti G, Cardona A: Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev, 2008:CD004388. This is an important systematic review challenging the benefit-to-risk ratio of activated protein C.

39.

• Levi M, Levy M, Williams MD, et al.: Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 2007, 176:483–490. This trial demonstrated no significant interaction between activated protein C and prophylactic heparin.CrossRefPubMed

40.

Vincent JL, Bernard GR, Beale R, et al.: Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 2005, 33:2266–2277.CrossRefPubMed

41.

Vincent J-L, O’Brien J Jr, Wheeler A, et al.: Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis. Crit Care 2006, 10:R74.CrossRefPubMed

Titel: Adjunct Therapy for Sepsis: How Early?
verfasst von: Djillali Annane
Publikationsdatum: 01.09.2010
Verlag: Current Science Inc.
Erschienen in: Current Infectious Disease Reports / Ausgabe 5/2010
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI: https://doi.org/10.1007/s11908-010-0123-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Adjunct Therapy for Sepsis: How Early?

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2010

Clinical Trial Report—Polymyxin B Hemoperfusion: Effective, or Not?

Nonbacterial Myositis

The Resuscitation Package in Sepsis

Early Fluid Resuscitation

Staphylococcal Toxic Shock Syndrome: Mechanisms and Management

Role of Echocardiogram in Decision Making for Surgery in Endocarditis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin